BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 14500357)

  • 1. Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors.
    Hackett CS; Hodgson JG; Law ME; Fridlyand J; Osoegawa K; de Jong PJ; Nowak NJ; Pinkel D; Albertson DG; Jain A; Jenkins R; Gray JW; Weiss WA
    Cancer Res; 2003 Sep; 63(17):5266-73. PubMed ID: 14500357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
    Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
    Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma.
    Cheng AJ; Cheng NC; Ford J; Smith J; Murray JE; Flemming C; Lastowska M; Jackson MS; Hackett CS; Weiss WA; Marshall GM; Kees UR; Norris MD; Haber M
    Eur J Cancer; 2007 Jun; 43(9):1467-75. PubMed ID: 17449239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma.
    Weiss WA; Godfrey T; Francisco C; Bishop JM
    Cancer Res; 2000 May; 60(9):2483-7. PubMed ID: 10811128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas.
    Fieuw A; Kumps C; Schramm A; Pattyn F; Menten B; Antonacci F; Sudmant P; Schulte JH; Van Roy N; Vergult S; Buckley PG; De Paepe A; Noguera R; Versteeg R; Stallings R; Eggert A; Vandesompele J; De Preter K; Speleman F
    Int J Cancer; 2012 Jun; 130(11):2599-606. PubMed ID: 21796619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.
    Althoff K; Beckers A; Bell E; Nortmeyer M; Thor T; Sprüssel A; Lindner S; De Preter K; Florin A; Heukamp LC; Klein-Hitpass L; Astrahantseff K; Kumps C; Speleman F; Eggert A; Westermann F; Schramm A; Schulte JH
    Oncogene; 2015 Jun; 34(26):3357-68. PubMed ID: 25174395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization.
    Scaruffi P; Parodi S; Mazzocco K; Defferrari R; Fontana V; Bonassi S; Tonini GP
    Mol Diagn; 2004; 8(2):93-100. PubMed ID: 15527323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosomes that show partial loss or gain in near-diploid tumors coincide with chromosomes that show whole loss or gain in near-triploid tumors: evidence suggesting the involvement of the same genes in the tumorigenesis of high- and low-risk neuroblastomas.
    Tomioka N; Kobayashi H; Kageyama H; Ohira M; Nakamura Y; Sasaki F; Todo S; Nakagawara A; Kaneko Y
    Genes Chromosomes Cancer; 2003 Feb; 36(2):139-50. PubMed ID: 12508242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes.
    Fix A; Lucchesi C; Ribeiro A; Lequin D; Pierron G; Schleiermacher G; Delattre O; Janoueix-Lerosey I
    Genes Chromosomes Cancer; 2008 Oct; 47(10):819-34. PubMed ID: 18553563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.
    Berbegall AP; Villamón E; Piqueras M; Tadeo I; Djos A; Ambros PF; Martinsson T; Ambros IM; Cañete A; Castel V; Navarro S; Noguera R
    Oncogene; 2016 Mar; 35(11):1423-32. PubMed ID: 26119945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in Wilms tumors.
    Schaub R; Burger A; Bausch D; Niggli FK; Schäfer BW; Betts DR
    Cancer Genet Cytogenet; 2007 Jan; 172(1):61-5. PubMed ID: 17175381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy.
    Passariello A; De Brasi D; Defferrari R; Genesio R; Tufano M; Mazzocco K; Capasso M; Migliorati R; Martinsson T; Siani P; Nitsch L; Tonini GP
    Eur J Med Genet; 2013 Nov; 56(11):626-34. PubMed ID: 24035971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there?
    Vandesompele J; Speleman F; Van Roy N; Laureys G; Brinskchmidt C; Christiansen H; Lampert F; Lastowska M; Bown N; Pearson A; Nicholson JC; Ross F; Combaret V; Delattre O; Feuerstein BG; Plantaz D
    Med Pediatr Oncol; 2001 Jan; 36(1):5-10. PubMed ID: 11464905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization.
    Scaruffi P; Coco S; Cifuentes F; Albino D; Nair M; Defferrari R; Mazzocco K; Tonini GP
    Cancer Genet Cytogenet; 2007 Aug; 177(1):20-9. PubMed ID: 17693187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.
    Rasmuson A; Segerström L; Nethander M; Finnman J; Elfman LH; Javanmardi N; Nilsson S; Johnsen JI; Martinsson T; Kogner P
    PLoS One; 2012; 7(12):e51297. PubMed ID: 23284678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction.
    Morowitz M; Shusterman S; Mosse Y; Hii G; Winter CL; Khazi D; Wang Q; King R; Maris JM
    Mod Pathol; 2003 Dec; 16(12):1248-56. PubMed ID: 14681326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression.
    Mosse YP; Diskin SJ; Wasserman N; Rinaldi K; Attiyeh EF; Cole K; Jagannathan J; Bhambhani K; Winter C; Maris JM
    Genes Chromosomes Cancer; 2007 Oct; 46(10):936-49. PubMed ID: 17647283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.
    Tomioka N; Oba S; Ohira M; Misra A; Fridlyand J; Ishii S; Nakamura Y; Isogai E; Hirata T; Yoshida Y; Todo S; Kaneko Y; Albertson DG; Pinkel D; Feuerstein BG; Nakagawara A
    Oncogene; 2008 Jan; 27(4):441-9. PubMed ID: 17637744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-resolution mapping of amplicons of the short arm of chromosome 1 in two neuroblastoma tumors by microarray-based comparative genomic hybridization.
    Fix A; Peter M; Pierron G; Aurias A; Delattre O; Janoueix-Lerosey I
    Genes Chromosomes Cancer; 2004 Jul; 40(3):266-70. PubMed ID: 15139005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.